注射用头孢唑肟钠国产品及进口品随机对照单盲治疗急性细菌性感染.docVIP

注射用头孢唑肟钠国产品及进口品随机对照单盲治疗急性细菌性感染 　【摘要】 目的 评价注射用头孢唑肟钠国产品 治疗 中、重度呼吸道细菌性感染的有效性和安全性。 方法 本临床试验选用两组药物，采用随机对照方法。试验药(注射用头孢唑肟钠国产品)和对照药(注射用头孢唑肟钠进口品)的剂量均为每次2g，Bid，疗程均为7～14d。结果 头孢唑肟钠国产品组与进口品组疗效评价例数分别为20例和21例，临床有效率分别为90.0%和90.5%，细菌清除率分别为94.4%和88.9%，药物不良反应发生率分别为0和4.8%，以上结果经统计学处理差异无显著性。结论 注射用头孢唑肟钠国产品与进口品在临床疗效、细菌学疗效、药物不良反应等方面无明显差异，且对敏菌引起的中重度感染疗效确切，药物不良反应少而轻微。 中国论文联盟编辑。 毕业论文 【关键词】 头孢唑肟钠； 细菌性感染； 临床疗效； 不良反应 毕业论文 A randomized, controlled, single blinded clinical study 论文代写 on domestic versus imported ceftizoxime sodium for 毕业论文 injection in the treatment of acute bacterial infections Cui Hong, Zhu Yan, Xue Feng and Xiao Yonghong (Institute of Clinical Pharmacology, the First Hospital of Peking University, BEijing 100034) 论文代写 ABSTRACT Objective To evaluate the clinical efficacy and safety of domestic ceftizoxime sodium for injection in the treatment of respiratory tract infections. Methods A randomized controlled, single blinded clinical trial was carried out in our centers. Domestic ceftizoxime sodium for injection was chosen as investigational drug, and imported one for controlled drug. Both drugs were administered intravenously at a dosage of 2g twice daily for 7～14 days. Results The efficacy rates were 90.0% and 90.5%, the bacterial clearance rates were 94.4% and 88.9%. The incidence of adverse drug reaction were 0.0% and 4.8% respectively between domestic and imported ceftizoxime sodium groups. There was no statistical significant difference between the two groups (Pgt;0.05). Conclusions Domestic ceftizoxime sodium for injection was effective and safe for the treatment of acute bacterial infections. 论文代写 KEY WORDS Ceftizoxime sodium; Bacterial infections; Efficacy; Safety 论文代写 注射用头孢唑肟钠(ceftizoxime sodium for injection)是日本藤泽药品 工业 株式会社20世纪80年代开发的第三代头孢菌素。头孢唑肟钠是一种氨基噻唑2甲氧亚胺基头孢菌素，对革兰阴性及革兰阳性菌有广泛的体外抗菌活性，尤其对肠道杆菌(包括产β内酰胺酶的菌株)的抗菌活性较强，对β内酰胺酶的水解作用高度稳定。但本品对葡萄球菌的活性不如第一、二代头孢菌素，对铜绿假单胞菌、肠球菌和脆弱拟杆菌的抗菌活性较差。该药的机体耐受性好，有良好的药动学特性，临床疗效显著［1～3］。本文报道国产注射用头孢唑肟钠的临床疗效与不良反应。